Table 6.
Frequency of single and concurrent TP53, PTEN, and CDKN2A alteration by WHO grade of malignancy.
| Gene Alterations | WHO Grading | |||
|---|---|---|---|---|
| Grade I | Grade II | Grade III | Grade IV | |
| One Gene | ||||
| TP53 */PTEN/CDKN2A | 1/8 (12.5%) | 1/18 (5.6%) | 2/13 (15.4%) | 2/23 (8.7%) |
| TP53/PTEN */CDKN2A | - | 1/18 (5.6%) | - | 5/23 (21.7%) |
| TP53/PTEN/CDKN2A* | - | 4/18 (22.2%) | 1/13 (7.7%) | 1/23 (4.3%) |
| Two Genes | ||||
| TP53*/PTEN */CDKN2A | - | - | - | 1/23 (4.3%) |
| TP53*/PTEN/CDKN2A* | 2/8 (25%) | - | 2/13 (15.4%) | 1/23 (4.3%) |
| TP53/PTEN */CDKN2A* | - | 1/18 (5.6%) | 2/13 (15.4%) | 6/23 (26.1%) |
| Three Genes | ||||
| TP53*/PTEN */CDKN2A* | - | 1/18 (5.6%) | 1/13 (7.7%) | 5/23 (21.7%) |
* alterated; - no alteration.